Literature DB >> 8182049

The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs.

J A DeMartino1, G Van Riper, S J Siciliano, C J Molineaux, Z D Konteatis, H Rosen, M S Springer.   

Abstract

The binding domain of the human C5a receptor consists of two distinct and physically separable subsites. One of these sites binds the C-terminal 8 amino acids of C5a and is as yet undefined, while the second site lies in the N terminus of the receptor and interacts with the core of C5a. Two deletion mutants were prepared to probe the importance of this second site. Removal of residues 2-22 decreased the binding affinity for C5a by 600-fold, while extending the deletion through residue 30 caused a further 75-fold decrease. Thus, the N terminus is responsible for at least 45% of the total energy for the binding of C5a. The five aspartic acids present in the deleted segments appear to be critical residues, as their conversion to alanines accounts for most of the affinity lost in the two truncations. Despite its importance for binding, the N terminus is not necessary for signal transduction, as a C-terminal peptide analog of C5a was able to stimulate G protein activation and to generate a Ca2+ flux through a receptor lacking residues 2-22. However, intact C5a was a very poor activator of this truncated receptor. These results imply that interaction between the N terminus of the receptor and C5a produces a conformational change in C5a that allows it's C terminus to properly interact with and activate the receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182049

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Characterization of Nef-CXCR4 interactions important for apoptosis induction.

Authors:  Ming-Bo Huang; Ling Ling Jin; Cleve O James; Mahfuz Khan; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 2.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

3.  Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.

Authors:  Elizabeth Buck; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 4.  Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1).

Authors:  B J Doranz; J F Berson; J Rucker; R W Doms
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

5.  Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.

Authors:  T M Woodruff; A J Strachan; S D Sanderson; P N Monk; A K Wong; D P Fairlie; S M Taylor
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

Review 6.  Receptors and G proteins as primary components of transmembrane signal transduction. Part 1. G-protein-coupled receptors: structure and function.

Authors:  T Gudermann; B Nürnberg; G Schultz
Journal:  J Mol Med (Berl)       Date:  1995-02       Impact factor: 4.599

7.  Structural mechanisms of constitutive activation in the C5a receptors with mutations in the extracellular loops: molecular modeling study.

Authors:  Gregory V Nikiforovich; Thomas J Baranski
Journal:  Proteins       Date:  2011-09-30

8.  Aptamers that bind to the human complement component receptor hC5aR1 interfere with hC5aR1 interaction to its hC5a ligand.

Authors:  Penmetcha K R Kumar
Journal:  Mol Biol Rep       Date:  2018-07-06       Impact factor: 2.316

9.  Antagonistic peptides against human anaphylatoxin C5a.

Authors:  Y Kaneko; N Okada; L Baranyi; T Azuma; H Okada
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

10.  Rhodopsin molecular evolution in mammals inhabiting low light environments.

Authors:  Huabin Zhao; Binghua Ru; Emma C Teeling; Christopher G Faulkes; Shuyi Zhang; Stephen J Rossiter
Journal:  PLoS One       Date:  2009-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.